Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cavo

Showing results (91-100 of 142) with videos related to

Pageof 15
Sort By:
Blood|February 15, 1996
Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cellsR M Lemoli, A Fortuna, M R Motta, et al.
Bone Marrow Transplantation|July 25, 1998
High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myelomaM Cavo, G Bandini, M Benni, et al.
Annals of Hematology|May 21, 2024
Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomesFrancesca Palandri, F Branzanti, M Venturi, et al.
Journal of Cancer Research and Clinical Oncology|October 9, 2025
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?M Talarico, S Barbato, V Maisnar, et al.
Leukemia|October 8, 2015
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myelomaM Cavo, L Pantani, A Pezzi, et al.
Leukemia|August 27, 2013
IMWG consensus on risk stratification in multiple myelomaW J Chng, A Dispenzieri, C-S Chim, et al.
British Journal of Haematology|December 3, 1999
Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot studyR M Lemoli, G Martinelli, A Olivieri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma NetworkE Terpos, O Sezer, P I Croucher, et al.
Journal of Bone Oncology|March 24, 2025
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myelomaM Talarico, S Barbato, A Cattabriga, et al.
Haematologica|May 16, 1998
Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantationR M Lemoli, G Bandini, G Leopardi, et al.
Pageof 15

Showing results (91-100 of 142) with videos related to

Sort By:
Pageof 15
Blood|February 15, 1996
Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cellsR M Lemoli, A Fortuna, M R Motta, et al.
Bone Marrow Transplantation|July 25, 1998
High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myelomaM Cavo, G Bandini, M Benni, et al.
Annals of Hematology|May 21, 2024
Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomesFrancesca Palandri, F Branzanti, M Venturi, et al.
Journal of Cancer Research and Clinical Oncology|October 9, 2025
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?M Talarico, S Barbato, V Maisnar, et al.
Leukemia|October 8, 2015
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myelomaM Cavo, L Pantani, A Pezzi, et al.
Leukemia|August 27, 2013
IMWG consensus on risk stratification in multiple myelomaW J Chng, A Dispenzieri, C-S Chim, et al.
British Journal of Haematology|December 3, 1999
Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot studyR M Lemoli, G Martinelli, A Olivieri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma NetworkE Terpos, O Sezer, P I Croucher, et al.
Journal of Bone Oncology|March 24, 2025
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myelomaM Talarico, S Barbato, A Cattabriga, et al.
Haematologica|May 16, 1998
Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantationR M Lemoli, G Bandini, G Leopardi, et al.
Pageof 15